2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

Crisp Therapeutics received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy in the world. Crispr shares were up close to 5% on the news. Don’t miss this list of 3 high-yield ...

These “zombie” cells are damaged yet refuse to die. Instead, they linger in the body, infect healthy cells, and can contribute to age-related decline. In this webinar, Janaina Sena and Debra Silver ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...